growth, and are unrelated to any systemic condition. 2, 4 Their clinical features are not yet well-defined. 1, 2 The etiology of the disease still remains uncertain, but it is suggested that congenital cases may represent melanocyte hamartomas. 2 Histology of the described cases of lingual melanotic macule reveals increased melanin in the basal cell layer, some pigment-laden macrophages in the dermis, normal number of melanocytes with no or a slight increase of melanin in their interior and variable degrees of hyperkeratosis. 2 There are no nests of melanocytes, atypia, or alterations in the lingual tissue, and, in some cases, slight elongation of the epithelial ridges has been described. 2 Also, according to Dohil et al. , no similar histopathological alteration was identified in the non-affected lingual tissue.
2
Our patient is an adult woman, which is uncommon when compared to other cases described. The most relevant differential diagnosis in this case would be to rule out the possibility of melanoma. A comparative study demonstrated similar efficacy of intralesional triamcinolone acetonide for the treatment of AA on the scalp regardless the concentration (2.5mg/mL, 5mg/mL, and 10mg/mL). However, the authors observed a lower risk of cutaneous atrophy at the lowest dose (2.5mg/mL). For the face, recommended concentrations of 2.5-5mg/mL have already been described, with a maximum concentration of 10mg/mL for the scalp, always respecting the maximum dose of 20mg per monthly session. 4 A possible option for the substitution of hexacetonide is betamethasone. 5 It is a low-cost, easy-to-access drug that has a formal recommendation for dermatological use in its package leaflet, which includes a specific indication for alopecia areata. In Brazil, there are two different options for betamethasone injectable suspension. The first one associates acetate salt with betamethasone disodium phosphate, both at a concentration of 3mg/mL. The second, combines dipropionate 5mg/mL with betamethasone disodium phosphate 2mg/mL.
Due to the ease of access to the drug, the latter is the authors' choice for the treatment of AA. For being more soluble, betamethasone dipropionate is rapidly absorbed. The less soluble disodium phosphate is absorbed more slowly and maintains an effective concentration of the drug for a longer time. Betamethasone is found as a sterile injectable suspension and is marketed in individual packs of 1 mL. This presentation minimizes contamination of the product as it allows for the disposal of the ampoule immediately after use.
A comparative study of intralesional triamcinolone and betamethasone for the treatment of oral lichen planus demonstrated greater efficacy and less recurrence of lesions with the use of betamethasone. 5 From a practical point of view, to infiltrate AA plaques using betamethasone (dipropionate 5mg/mL + disodium phosphate 2mg/mL), drug dosage should be initially calculated using the 2.5mg/mL triamcinolone concentration as a basis. This concen- The use of topical anesthetics, vibration, and pre-cooling of injection site may be useful to minimize procedural pain. Treatment should be discontinued if there is no improvement after six months of infiltration. 2 Therefore, because it is viewed as a consecrated medication with a high anti-inflammatory potential, low cost, easy access, and with dermatological indication formalized in the package leaflet, betamethasone injectable suspension seems to be a good option to be considered as an alternative to triamcinolone in the intralesional treatment of alopecia areata. q
